Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Temozolomide & Radiation Therapy Clear all
Completed Phase 2 Interventional Results available

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

NCT00763750
View directory record Official record
Conditions
Brain Tumor
Interventions
PPX +TMZ+XRT
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma

NCT03278249
View directory record Official record
Conditions
Glioblastoma
Interventions
Modified Atkins Ketogenic Diet
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT00916409
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
NovoTTF-100A device, Temozolomide
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

NCT00660543
View directory record Official record
Conditions
Adult Brain Glioblastoma
Interventions
Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

NCT00458601
View directory record Official record
Conditions
Malignant Glioma
Interventions
CDX-110 with GM-CSF, Temozolomide
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
34
States / cities
Orange, California • San Francisco, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 9, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma

NCT03168919
View directory record Official record
Conditions
Glioma
Interventions
Fractionated Radiation, Temozolomide, MRI
Radiation · Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 9, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

NCT02046187
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Ketogenic Diet, Radiation therapy, Temozolomide
Dietary Supplement · Radiation · Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

NCT03514069
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
ruxolitinib, radiation, temozolomide
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

NCT00100802
View directory record Official record
Conditions
Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma, Spinal Cord Neoplasm
Interventions
Laboratory Biomarker Analysis, Lomustine, Radiation Therapy, Temozolomide
Other · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 9, 2026, 5:10 AM EDT
Not listed Phase 1Phase 2 Interventional

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

NCT00394628
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
AQ4N, Temozolomide, Radiotherapy
Drug · Procedure
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 9, 2026, 5:10 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma

NCT04555577
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Peposertib, Radiation Therapy, Resection, Temozolomide
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

NCT00028795
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
202
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT03425292
View directory record Official record
Conditions
Newly Diagnosed High Grade Glioma
Interventions
Temozolomide, conformal brain radiation therapy, Nivolumab, Ipilimumab, Bevacizumab, 5-day Temozolomide, Lomustine, Nivolumab monotherapy
Drug · Radiation
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 9, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma

NCT00936052
View directory record Official record
Conditions
Glioblastomas, Gliosarcoma
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Neurological Surgery, P.C.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Commack, New York • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 9, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional

Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM

NCT00548938
View directory record Official record
Conditions
Glioblastoma Multiforme, High-Grade Glioma
Interventions
Gliadel wafer, Temozolomide, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 9, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
View directory record Official record
Conditions
Malignant Glioma
Interventions
Nuvigil®, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

NCT01653834
View directory record Official record
Conditions
Glioblastoma
Interventions
Lymphocyte harvesting & reinfusion
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

NCT04757662
View directory record Official record
Conditions
Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
Interventions
Tadalafil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 9, 2026, 5:10 AM EDT
Not listed No phase listed Observational

MRI Predictors of Response to Tumor Treating Fields

NCT03642080
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Not listed
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 9, 2026, 5:10 AM EDT
Recruiting Phase 3 Interventional

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT07195591
View directory record Official record
Conditions
Glioblastoma
Interventions
GammaTile®, External Beam Radiation Therapy, Temozolomide
Device · Radiation · Drug
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

UNITE Study: Understanding New Interventions With GBM ThErapy

NCT03419403
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Steroid eye drops, Vasoconstrictor eye drops, Cold compress, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide, Radiation
Drug · Other · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 9, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

NCT00960492
View directory record Official record
Conditions
Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
Interventions
XL184, temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 9, 2026, 5:10 AM EDT